Author:
Eedara Basanth Babu,Tucker Ian G.,Das Shyamal C.
Abstract
AbstractIn vitro dissolution testing is a useful quality control tool to discriminate the formulations and to approximate the in vivo drug release profiles. A dissolution apparatus has been custom-made for dissolution testing of dry powder formulations in a small volume of stationary medium (25 μL spread over 4.91 cm2 area i.e. ~50 μm thick). To understand the system and predict the key parameters which influence the dissolution of respirable size particles, a simulation model was constructed using STELLA modeling software. Using this model, the permeation (dissolution followed by diffusion through the membrane) of two anti-tubercular drugs of differing solubilities, moxifloxacin (17.68 ± 0.85 mg mL−1) and ethionamide (0.46 ± 0.02 mg mL−1), from the respirable size particles and their diffusion from a solution were simulated. The simulated permeation profiles of moxifloxacin from solution and respirable size particles were similar, indicating fast dissolution of the particles. However, the simulated permeation profile of ethionamide from respirable size particles showed slower permeation compared to the solution indicating the slow dissolution of the respirable size particles of ethionamide. The sensitivity analysis suggested that increased mucus volume and membrane thickness decreased the permeation of drug. While this model was useful in predicting and distinguishing the dissolution behaviours of respirable size moxifloxacin and ethionamide, further improvement could be made using appropriate initial parameter values obtained by experiments.
Funder
Manatu Hauora | Health Research Council of New Zealand
Publisher
Springer Science and Business Media LLC
Reference49 articles.
1. FDA, U. Guidance for Industry: Dissolution testing of immediate-release solid oral dosage forms. Food and Drug Administration, Center for Drug Evaluation and Research (CDER) (1997).
2. Gray, V. A. et al. The inhalation ad hoc advisory panel for the USP performance tests of inhalation dosage forms. Pharma. Forum 34, 1068–1074 (2008).
3. Son, Y.-J., Mitchell, J. P. & McConville, J. T. In vitro performance testing for pulmonary drug delivery. In Controlled Pulmonary Drug Delivery (eds Smyth, H. D. C. & Hickey. A. J.) 383-415 (Springer New York, 2011).
4. Patton, J. S. & Byron, P. R. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discov. 6, 67–74 (2007).
5. Eedara, B. B., Tucker, I. G. & Das, S. C. In vitro dissolution testing of respirable size anti-tubercular drug particles using a small volume dissolution apparatus. Int. J. Pharm. 559, 235–244 (2019).
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献